Cotransplantation of haploidentical hematopoietic stem cells and allogeneic bone marrow‐derived mesenchymal stromal cells as a first‐line treatment in very severe aplastic anemia patients with refractory infections

Abstract

Upfront HRD-HSCT may be a safe and promising choice for patients with VSAA in critical situations without suitably matched donors.